-
Evaluation of Torque Teno Virus DNA Load as a Predictive Biomarker in Kidney Transplant Recipients Converted from Calcineurin Inhibitors to Belatacept Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-11 Lara Cabezas MD, Aurelie Truffot PD, Raphaele Germi PhD, Mathilde Bugnazet MS, Paolo Malvezzi MD, Manon Gnesotto MS, Lionel Rostaing PhD, Thomas Jouve PhD, Johan Noble MD
Belatacept is a relevant alternative to calcineurin-inhibitors after kidney transplantation. Circulating Torque Teno Virus (TTV) DNA load is correlated to infectious and rejection risks post-kidney transplantation in calcineurin-inhibitors treated patients. The aim of this study was to assess the TTV DNA load profile in kidney transplant recipients converted from calcineurin-inhibitors to Belatacept
-
Multiomics assessment of the gut microbiome in rare hyperoxaluric conditions Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-11 Nadim Zaidan, Chan Wang, Ze Chen, John C. Lieske, Dawn Milliner, Barbara Seide, Melody Ho, Huilin Li, Kelly V. Ruggles, Frank Modersitzki, David S. Goldfarb, Martin Blaser, Lama Nazzal
Hyperoxaluria is a risk factor for kidney stone formation and chronic kidney disease progression. The microbiome is an important protective factor against oxalate accumulation through its oxalate-degrading enzyme activity. In this cross-sectional study, we leverage multi-omics to characterize the microbial community of participants with primary and enteric hyperoxaluria, as well as idiopathic calcium
-
Sex-specific association of ambient temperature with urine biomarkers in Southwest Coastal Bangladesh Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-11 Hoimonty Mazumder, Momenul Haque Mondol, Mahbubur Rahman, Rizwana Khan, Solaiman Doza, Leanne Unicomb, Farjana Jahan, Ayesha Mukhopadhyay, Konstantinos Makris, Alberto Caban-Martinez, Romaina Iqbal, Faruk Ahmed, Lota Creencia, Mohammad Shamsudduha, Fawaz Mzayek, Chunrong Jia, Hongmei Zhang, Anwar Musah, Lora E. Fleming, Xichen Mou, Csaba P. Kovesdy, Matthew O. Gribble, Abu Mohd Naser
Men are vulnerable to ambient heat-related kidney disease burden, but limited evidence exists on how vulnerable women are when exposed to high ambient heat. We evaluated the sex-specific association between ambient temperature and urine electrolytes (concentration and 24-hour excretion), and 24-hour urine total protein, and volume. We pooled a longitudinal data of 1,175 participants' concentration
-
Role of iron in children with IgA nephropathy and macrohematuria-induced acute kidney injury Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-09 Shingo Ishimori M.D. Ph.D., Tomoko Horinouchi M.D. Ph.D., Tomohiko Yamamura M.D. Ph.D., Junya Fujimura M.D. Ph.D., Naohiro Kamiyoshi M.D. Ph.D., Hiroshi Kaito M.D. Ph.D., Yuriko Tanaka M.D. Ph.D., Hiroyoshi Matsukura M.D. Ph.D., Wataru Shimabukuro M.D. Ph.D., Yuko Shima M.D. Ph.D., Azusa Kawaguchi M.D. Ph.D., Yoshinori Araki M.D. Ph.D., Koichi Nakanishi M.D. Ph.D., Shigeo Hara M.D. Ph.D., Kandai Nozu
The role of iron in, and the prognosis of, pediatric IgA nephropathy (IgAN) with macrohematuria-induced acute kidney injury (MH-AKI) have not been evaluated. Thirty percent of adults with MH-AKI, and especially those who are older, show progression to chronic kidney disease. We evaluated the immunohistopathologic characteristics of renal biopsy samples from pediatric patients with MH-AKI IgAN and controls
-
Pregnancy and Family Planning in Women with Kidney Disease Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-06 Joy Eskandar, Anika Lucas MD, Angelina Dixon MD, Jessica Kendrick MD MPH
Females with kidney disease are at increased risk for pregnancy complications. Few studies have examined pregnancy perspectives of people with kidney disease. Our objective was to examine kidney patients perspectives on family planning. We conducted an online survey of female patients with kidney disease from the University of Colorado Hospital between the ages of 18 and 50 years from August to October
-
Predictive Factors of Renal Recovery and Progression to End-Stage Kidney Disease in Patients with ANCA-Associated Vasculitis with Severe Kidney Disease Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-06 Marta Casal Moura MD MSc MSPH, Dalia Zubidat MD, Marc Patricio Liebana MD, Sanjeev Sethi MD PhD, Maria Jose Soler MD PhD, Ladan Zand MD, Fernanda G. dos Santos MD, Luca Nardelli MD, Juan Leon-Roman MD, Ciria Sousa MD, Kenneth J. Warrington MD, Ulrich Specks MD, Fernando C. Fervenza MD PhD
A significant number of patients with anti-neutrophil cytoplasmic antibodies (ANCA) associated vasculitis (AAV) with glomerulonephritis (AAV-GN) still progress to end-stage kidney disease (ESKD, eGFR<15mL/min/1.73m) despite advances in remission-induction treatment. A retrospective cohort study on MPO- or PR3-ANCA positive patients with AAV (MPA or GPA) and eGFR<15 ml/min/1.73 m or ESKD at presentation
-
Associations between prematurity, birth weight and adolescence blood pressure in a nationwide cohort Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-01 Shimrit Tzvi-Behr, Lucy Balagour Greenstein, Efrat Ben-Shalom, Yaacov Frishberg, Sharon Ohayon Cohen
Prematurity is associated with incomplete nephrogenesis and an increased incidence of acute kidney injury, that may increase the risk of future kidney disease, including hypertension, proteinuria and reduced glomerular filtration rate. Study cohort included potential recruits examined in the Israel Defence Forces (IDF) medical facilities, between November 2005 and October 2018. Clinical and anthropometric
-
Narrative Review of Immunomodulatory and Anti-Inflammatory Effects of SGLT2 Inhibitors: Unveiling Novel Therapeutic Frontiers Kidney Int. Rep. (IF 6.0) Pub Date : 2024-03-01 Sul A. Lee, Leonardo V. Riella
Sodium-glucose cotransporter 2 inhibitors (SGLT2 inhibitors) have evolved from their initial role as anti-diabetic drugs to garner recognition for their remarkable cardio-protective and reno-protective attributes. They have become a crucial component of therapeutic guidelines for congestive heart failure and proteinuric chronic kidney disease. These benefits extend beyond glycemic control, as improvements
-
Realtime Remote Detection of Evolving Peritonitis in Peritoneal Dialysis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-29 Mark Lambie, Martin Wilkie
-
Clinical Characteristics and Outcomes of Neural Epidermal Growth Factor-like 1 Protein-Associated Membranous Nephropathy Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-24 Suruthy Narayanasami, Niranjan Anitha Vijayakumar, Mayuri Trivedi, Aravind Sekar, Shabna Sulaiman, Saurabh Nayak, Neeraj Inamdar, Sourabh Sharma, Rajeevalochana Parthasarathy, Vidya Kadam, Vaibhav Keskar, Sahil Bagai, Ashwani Kumar, Bajinder Reen, Anila Abraham Kurien, Alok Sharma, Dinesh Khullar, Benil Hafeeq, Arvind Krishnakumar, Shafeeque Rahman KV, Ismail NA, Sanjeev Nair, Smita Divyaveer, Manish
-
Fournier's Gangrene in a Patient With CKD Without Diabetes Possibly Related to Sodium-Glucose Cotransporter 2 Inhibitor Therapy Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-24 Isabel Heidegger, Marit Zwierzina, Jan Boeckhaus, Vera Krane, Oliver Gross
-
Clinical Remission and Reduction of Circulating Nephritic Factors by Combining Rituximab With Belimumab in a Case of Complement Factor 3 Glomerulopathy Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-24 Mieke van Schaik, Aiko P.J. de Vries, Frederike J. Bemelman, Ton J. Rabelink, Leendert A. Trouw, Cees van Kooten, Y.K. Onno Teng
-
Characteristics and Outcomes of NELL1 Membranous Nephropathy in Lipoic Acid Users and Nonusers Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-24 Rupali S. Avasare, Samantha Clark, Rebecca I. Spain, Raghav Wusirika, Robert Rope, Susan Gurley, Madison Stanaway, Miroslav Sekulic, Dominick Santoriello, Andrew S. Bomback, Pietro Canetta, Sitalakshmi J. Iyer, Vanderlene Kung, Vivek Charu, Megan L. Troxell, Satoru Kudose, Nicole K. Andeen
Neural epidermal growth factor like 1 membranous nephropathy (NELL1 MN) is associated with various secondary etiologies. However, previous studies on the frequency of these associations and their impact on outcomes are limited. We report a large multiinstitutional series of patients with NELL1 MN with a focus on secondary associations, pathology findings, and their impact on outcome. We retrospectively
-
Pilot Study of sC5b-9 and Bb Fragment Plasma Levels in Crescentic Immunoglobulin A Nephropathy Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-23 Gabriella Guzzo, Salima Sadallah, Valentin Rousson, Francisco Herrera-Gómez, Giuseppe Pantaleo, Manuel Pascual, Daniel Teta
-
Renal Disease in Metabolic Syndrome: the Hidden Role of Intrarenal Ischemia Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-22 Rosa Rodríguez-Rodríguez, Mads Hornum, Ana Elena Rodríguez Rodríguez, Sebastjan Bevc, Francesco Trevisani, Gema Fernández, Radovan Hojs, Beatriz Fernández-Fernández, Clara María Cases Corona, Josep María Cruzado, María Quero, Maruja Navarro Díaz, Arianna Bettiga, Francisco Moreso, Clara García Carro, Khaled Khazim, Fedaa Ghanem, Meritxell Ibernón, Ivo Laranjinhia, Luís Mendonça, Miguel Bigotte Vieira
The pathogenesis of renal disease in obesity and metabolic syndrome (MS) is mostly unknown. This is in part because of the limited information about renal morphological changes in these conditions. We evaluated renal histology in subjects with MS and those without MS, who are participants in the European Nephrectomy Biobank (ENBiBA) project. MS was defined with at least 3 of the following criteria:
-
Longitudinal Trajectories of Biomarkers of Kidney Tubular Function in Type 1 Diabetes Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-18 Christine P. Limonte, Xiaoyu Gao, Ionut Bebu, Jesse C. Seegmiller, Gayle M. Lorenzi, Bruce A. Perkins, Amy B. Karger, Valerie L. Arends, Andrew Paterson, Mark E. Molitch, Ian H. de Boer, DCCT/EDIC Research Group
Tubular biomarkers may shed insight into progression of kidney tubulointerstitial pathology complementary to traditional measures of glomerular function and damage. We examined trajectories of tubular biomarkers in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications Study (DCCT/EDIC Study) of type 1 diabetes (T1D). Biomarkers were measured in
-
Utility of routine post kidney transplant anti-HLA antibody screening Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-18 Sofiane Salhi, Nicolas Congy-Jolivet, Anne-Laure Hebral, Laure Esposito, Guillaume Vieu, Jean Milhès, Nassim Kamar, Arnaud Del Bello
DSA (dnDSA) is a strong biomarker associated with the development of antibody mediated rejection and graft loss after kidney transplantation. Although this procedure is expensive, systematic annual screening was recommended by some national organ transplant agencies or societies though its clinical utility was not clearly established. To address this question, we retrospectively assessed the incidence
-
A prospective study of the association between plasma calprotectin levels and new-onset chronic kidney disease in the general population Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-16 Arno R. Bourgonje, Martin F. Bourgonje, Sacha la Bastide-van Gemert, Tom Nilsen, Clara Hidden, Ron T. Gansevoort, Douwe J. Mulder, Jan-Luuk Hillebrands, Stephan J.L. Bakker, Robin P.F. Dullaart, Harry van Goor, Amaal E. Abdulle
Systemic inflammation has been associated with chronic kidney disease (CKD). In this study, we aimed to investigate a potential association between the plasma biomarker of inflammation calprotectin and new-onset CKD in a population-based cohort study. Individuals without CKD at baseline (=4,662) who participated in the Prevention of REnal and Vascular ENd-stage Disease (PREVEND) prospective population-based
-
Clinical Presentation, Pathological Spectrum, and Outcomes of Alcoholic Cirrhosis-Related Immunoglobulin A Nephropathy Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-16 Charles Ronsin, Pierre Braud, Christine Kandel-Aznar, Amaury Dujardin, Clémence Petit, David Larmet, Claire Garandeau, Clément Deltombe, Alice Le Clech, Claire Leman, Gilles Blancho, Juliet Schurder, Grégoire Couvrat-Desvergnes, Simon Ville
Immunoglobulin A nephropathy (IgAN) associated with cirrhosis is frequent but often overlooked because it is largely considered silent. Until now, little has been known about their presentation and outcomes. We conducted a retrospective multicenter study on patients with kidney biopsy-proven cirrhosis-related IgAN (cirrhosis-IgAN), diagnosed between 2009 and 2022. We mixed them up with 83 primary IgAN
-
Update thiazide diuretic evidence review for CARI Guidelines kidney stones recommendations Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-16 David J. Tunnicliffe, Andrew Mallet, Brydee Cashmore, Adam Mullan, Lyn Lloyd, Adela Yip, Ieuan Wickham, Hicham Hassan, Matthew Jose
-
Aversion to a High Salt Taste is Disturbed in Patients With CKD Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-16 Natsuko Okuno-Ozeki, Yusuke Kohama, Hiromu Taguchi, Yuka Kawate, Minato Umehara, Atsushi Minamida, Hiroko Yamauchi-Sawada, Yasuto Sunahara, Yayoi Matoba, Itaru Nakamura, Kunihiro Nakai, Tomohiro Nakata, Yuhei Kirita, Takuya Taniguchi, Keiichi Tamagaki, Takashi Hirao, Satoaki Matoba, Tetsuro Kusaba
A reduced salt intake is a vital lifestyle modification in the management of hypertension. Initiatives aimed at decreasing the intake of salt are based on the preference by humans for a salt taste. Salt intake behavior appears to be affected by the balance between attraction to a low salt taste and aversion to a high salt taste. However, aversion to a high salt taste has not yet been quantitively investigated
-
Early Rituximab as an Add-On Therapy in Children With the Initial Episode of Nephrotic Syndrome Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-16 Jialu Liu, Fang Deng, Xiaowen Wang, Cuihua Liu, Shuzhen Sun, Ruifeng Zhang, Aihua Zhang, Xiaoyun Jiang, Weili Yan, Yalan Dou, Yi Zhang, Li Xie, Biyun Qian, Qian Shen, Hong Xu
The approximately 70% 12-month relapse in children experiencing the initial episode of steroid-sensitive nephrotic syndrome (SSNS) is a significant concern, with over 50% developing frequent relapses or steroid-dependent nephrotic syndrome (FRNS/SDNS). There is a lack of strategies to reduce relapse after the onset. Whether early administration of rituximab, which effectively reduces relapses in FRNS/SDNS
-
Immune checkpoint therapy–induced lupus nephritis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-16 Imran Humza Hanif, Saifudeen Abdelrahim, Majd Al Shaarani, Huifang Lu, Raisa Ahmad, Sangeeta Goswami, Ala Abudayyeh
-
Associations With Baseline Blood Pressure Control in NURTuRE-CKD Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-15 Bethany J. Lucas, Paul Cockwell, Simon D.S. Fraser, Philip A. Kalra, David C. Wheeler, Maarten W. Taal
-
Genetic Diagnosis of Adult Hemodialysis Patients With Unknown Etiology Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-14 Takuya Fujimaru, Takayasu Mori, Motoko Chiga, Shintaro Mandai, Hiroaki Kikuchi, Fumiaki Ando, Yutaro Mori, Koichiro Susa, Yuta Nakano, Takao Shoji, Yuichiro Fukudome, Naoto Inaba, Kenichiro Kitamura, Taichi Nakanishi, Keiko Uchida, Toshihiro Kimura, Teiichi Tamura, Kiyoshi Ozawa, Shinichi Uchida, Eisei Sohara
-
A Pilot Study on the Safety and Adequacy of a Novel Eco-friendly Hemodialysis Prescription – Green Nephrology Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-13 Solomon Dolphin, Arumugam Venkatesh, Sakthirajan Ramanathan, Lamech Tanuj Moses, Dineshkumar Thanigachalam, Vathsalyan Paulpandiyan, Senthilkumaran Guhan, Krishna Ravindran, Shaji Sajmi, Gopalakrishnan Natarajan
-
Rationale and Design of a of a Phase 2, Double-blind, Placebo-controlled, Randomized Trial Evaluating AMPK-activation by Metformin in Focal Segmental Glomerulosclerosis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-13 Gabriel C. Barsotti, Randy Luciano, Ashwani Kumar, Kristin Meliambro, Vijayakumar Kakade, Joji Tokita, Abhijit Naik, Jia Fu, Elizabeth Peck, John Pell, Anand Reghuvaran, E.M. Tanvir, Prashant Patel, Weijia Zhang, Fan Li, Gilbert Moeckel, Sudhir Perincheri, Lloyd Cantley, Dennis G. Moledina, F. Perry-Wilson, John C. He, Madhav C. Menon
-
Updating the Data: The Resource Consumption of Modern-Day Hemodialysis Systems Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-12 Katherine A. Barraclough, Steve Moller, Susan Blair, Richard Knight, John Agar, Scott McAlister, Anthea White, Matthew Sypek
-
Randomized Trial on the Efficacy and Safety of Standard Versus Higher Bicarbonate Supplementation in CKD of Unknown Etiology Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-12 Swathy Raju, Karthikeyan Manoharan, Natarajan Ramachandran, Jayaprakash Sahoo, Balasubramanian Vairappan, Velkumary Subramaniyam, Sreejith Parameswaran, P.S. Priyamvada
-
Sex Inequities in Clinical Trials and Trial Leadership Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-11 Anna Francis, Adeera Levin
-
Kidney Tissue Proteome Profiles in Short Versus Long Duration of Delayed Graft Function - A Pilot Study in Donation After Circulatory Death Donors Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-10 M. Letizia Lo Faro, Kaithlyn Rozenberg, Honglei Huang, Sergei Maslau, Sarah Bonham, Roman Fischer, Benedikt Kessler, Henri Leuvenink, Edward Sharples, Jan H. Lindeman, Rutger Ploeg
Delayed graft function (DGF) is often defined as the need for dialysis treatment in the first week after a kidney transplantation. This definition, though readily applicable, is generic and unable to distinguish between “types” of DGF or time needed to recover function that may also significantly affect longer-term outcomes. We aimed to profile biological pathways in DCD kidney donors that correlate
-
Modification of Dialysate Na+ Concentration but not Ultrafiltration or Dialysis Treatment Time Affects Tissue Na+ Deposition in Patients on Hemodialysis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Christoph Kopp, Lukas Kittler, Peter Linz, Dennis Kannenkeril, Stephan Horn, Charles Chazot, Mario Schiffer, Michael Uder, Armin M. Nagel, Anke Dahlmann
Tissue Na overload is present in patients receiving hemodialysis (HD) and is associated with cardiovascular mortality. Strategies to actively modify tissue Na amount in these patients by adjusting the HD regimen have not been evaluated. In several substudies, including cross-sectional analyses ( = 75 patients on HD), a cohort study and a cross-over interventional study ( = 10 patients each), we assessed
-
Corrigendum to “Classifying Hypotonic Hyponatremia by Projected Treatment Effects - A Quantitative 3-Dimensional Framework” [Kidney International Reports Volume 8, Issue 12, December 2023, Pages 2720-2732] Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Florian Buchkremer, Philipp Schuetz, Beat Mueller, Stephan Segerer
-
A Post Hoc Analysis of the CKD-FIX Study Analyzing the Association Between Metformin Usage and Estimated GFR Decline Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Isabelle Kitty Stanley, Andrew J. Mallett, Andrea K. Viecelli, Carmel M. Hawley, Christine E. Staatz, David W. Johnson, Elasma Milanzi
-
Effect of Intravitreal Anti-Endothelial Growth Factor Agents on Renal Function in Patients With Diabetes Mellitus Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Marta Rivero, María Fernández-Vidal, Justo Sandino, Raquel Berzal Rico, Candela Moliz, José Enrique Ruiz-Cabello, Lucía Cordero Garcia-Galán, Celia González-García, Paúl Hernández-Velasco, Julián Segura, Eduardo Gutiérrez, Enrique Morales
Intravitreal administration of vascular endothelial growth factor inhibitors (anti-VEGF) is the treatment of choice in retinal pathology associated with type 2 diabetes mellitus (DM2). We aimed to analyze the effect of intravitreal anti-VEGF administration on renal function in patients with DM2. This is a single-center retrospective and observational study of patients with DM2 with and without chronic
-
Effectiveness of molnupiravir and nirmatrelvir–ritonavir in CKD patients with COVID-19. Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Franco Wing Tak Cheng, Vincent Ka Chun Yan, Eric Yuk Fai Wan, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Carlos King Ho Wong, Xue Li, Irene Ran Zhang, Sydney Chi Wai Tang, Ian Chi Kei Wong, Esther Wai Yin Chan
Even with effective vaccines, patients with CKD have a higher risk of hospitalization and death subsequent to COVID-19 infection compared with those without CKD. Molnupiravir and nirmatrelvir-ritonavir have been approved for emergency use, but their effectiveness for the CKD population is still unknown. This study was conducted to determine the effectiveness of these drugs in reducing mortality and
-
Aortic Dilatation in Children and Young People With ADPKD Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Alexandra Savis, Emily Haseler, Hayley Beardsley, Phil J. Chowienczyk, John M. Simpson, Manish D. Sinha
Aortic root dilatation is a reported cardiovascular sequela seen in children and young people (CYP) with chronic kidney disease (CKD), but has yet to be described in those with Autosomal dominant polycystic kidney disease (ADPKD). Single centre, cross-sectional study in a dedicated ADPKD clinic. Echocardiograms were evaluated for the presence of dilatation [defined by a z-score ≥2 (≥99 percentile)
-
Effects of Medications on the in vitro Growth of Gut Bacteria Associated With Kidney Stones Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Jing Bi-Karchin, Dylan Curry, Elliot S. Friedman, Michelle Denburg, Gregory E. Tasian
-
A Transplant-Inclusive Value-Based Kidney Care Payment Model Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-09 Benjamin E. Hippen, George M. Hart, Franklin W. Maddux
In the United States, kidney care payment models are migrating toward value-based care (VBC) models incentivizing quality of care at lower cost. Current kidney VBC models will continue through 2026. We propose a future transplant-inclusive value-based care (TIVBC) model designed to supplement current models focusing on patients with advanced chronic kidney disease (CKD) and end stage kidney disease
-
Uptake and Outcomes of Peritoneal Dialysis among Aboriginal and Torres Strait Islander People: Analysis of Registry Data Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-06 Hayat A, Cho Y, Pascoe EM, Krishnasamy R, Borlace M, Chen J, Boudville N, Sud K, Varnfield M, Francis R, Pitt R, Hughes JT, Johnson DW
Peritoneal dialysis (PD) enables people to utilise kidney replacement therapy (KRT) outside of health-care-dependent settings, a strong priority of Aboriginal and Torres Strait Islander people. We undertook an observational study analysing registry data to describe access to PD and its outcome as the first KRT among Aboriginal and Torres Strait Islander people between 1 Jan. 2004 and 31 Dec. 2020.
-
Bone Marrow Oxalosis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-06 Thibaut d’Izarny-Gargas, Julien Dang, Anne Grünenwald, Zeina Mechref, Florent L. Besson, Sophie Ferlicot, Mohamad Zaidan
-
Relevance of tacrolimus trough concentration and Hepatitis E virus genetic changes in kidney transplant recipients with chronic hepatitis E Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-06 Nancy León-Janampa, Natacha Boennec, Olivier Le Tilly, Simon Ereh, Gabriel Herbet, Alain Moreau, Philippe Gatault, Hélène Longuet, Christelle Barbet, Mathias Buchler, Christophe Baron, Catherine Gaudy-Graffin, Denys Brand, Julien Marlet
Hepatitis E virus (HEV) can cause chronic infection (≥3 months) and cirrhosis in immunocompromised patients, especially kidney transplant recipients. Low ALT levels and high HEV intra-host diversity have previously been associated with evolution toward chronicity in these patients. We hypothesized that additional clinical and viral factors could be associated with the risk of chronic HEV infection
-
Exposome and Metabolome Analysis of Sugarcane Workers Reveals Predictors of Kidney Injury Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-06 Arthur D. Stem, Stephen Brindley, Keegan L. Rogers, Adil Salih, Carlos A. Roncal-Jimenez, Richard J. Johnson, Lee S. Newman, Jaime Butler-Dawson, Lyndsay Krisher, Jared M. Brown
Sugarcane workers are exposed to potentially hazardous agrochemicals including pesticides, heavy metals, and silica. Such occupational exposures present health risks and have been implicated in a high rate of kidney disease seen in these workers. To investigate potential biomarkers and mechanisms that could explain chronic kidney disease (CKD) among this worker population, paired urine samples were
-
Reclassification of Variants Following Renal Genetics Testing: Uncommon Yet Impactful for Diagnosis and Management Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-05 Euyn Lim, Chloe Borden, Seysha Mehta, Mary-Beth Roberts, Sarah Mazzola, Fang Zhao, Xiangling Wang
Genetic testing is increasingly utilized in nephrology practice while limited real-world data exist on variant reclassification following renal genetics testing. A cohort of patients at the Cleveland Clinic Renal Genetics Clinic who underwent genetic testing through clinical laboratories was assessed with clinical and laboratory data analyzed. Between January 2019 and June 2023, 425 new patients with
-
How does ADPKD severity differ between family members? Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-05 Klement C. Yeung, Elise Fryml, Matthew B. Lanktree
Thousands of pathogenic variants in more than 100 genes can cause kidney cysts with substantial variability in phenotype and risk of subsequent kidney failure. Despite an established genotype-phenotype correlation in cystic kidney diseases, incomplete penetrance and variable disease expressivity are present as is the case in all monogenic diseases. In family members with autosomal dominant polycystic
-
Modifiable Physical Factors That Influence Physical Function for People Receiving Peritoneal Dialysis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-05 Brett Tarca, Shilpanjali Jesudason, Paul N. Bennett, Thomas P. Wycherley, Katia E. Ferrar
People receiving peritoneal dialysis experience physical function decline, impairing their ability to complete everyday activities, leading to poorer quality of life. Physical factors including cardiorespiratory fitness, muscle strength, physical activity and sedentary behaviour are associated with physical function. However, little is known about this relationship, or temporal changes of these factors
-
Epidemiology of End-Stage Kidney Disease in French Polynesia: A Plea for Standardized Diagnosis Workflow in Young Adults of First Nations People Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-04 Lorraine Gueguen, Belinda Boyle, Valérie Chune, Marine Dancer, Sylvie Leou, Pascale Testevuide, Ronan Delaval, Stanislas Faguer
Abstract not available
-
Dialysis ECHO: An Educational Solution to Improve Dialysis Care in Low-Resource and High-Demand Settings Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-03 Azza E. Abdalla, Ahmed J. Abdelrahim, Ali S. Warrag, Abubaker S. Farah, Duaa S. Mahmoud, Salaheldin A. Abusin, Elwaleed A. Elhassan, Roberto Pecoits-Filho
Abstract not available
-
Description of a New Simple and Cost-Effective Molecular Testing That Could Simplify MUC1 Variant Detection Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-03 Victor Fages, Florentin Bourre, Romain Larrue, Andrea Wenzel, Jean-Baptiste Gibier, Fabrice Bonte, Claire-Marie Dhaenens, Kendrah Kidd, Stanislav Kmoch, Anthony Bleyer, François Glowacki, Olivier Grunewald
Patients with Autosomal Dominant Tubulointerstitial Kidney Disease (ADTKD) usually present with non-specific progressive chronic kidney disease with mild to negative proteinuria and a family history. ADTKD- leads to the formation of a frameshift protein (MUC1fs) that accumulates in the cytoplasm, leading to tubulo-interstitial damage. ADTKD- prevalence remains unclear as variants are not routinely
-
Occurrence of Lupus-Like Nephritis in a Girl With NLRC4 Gain-of-Function Mutations Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-02 Franck Zekre, Audrey Laurent, Bruno Ranchin, Anne-Perrine Foray, Marine Thilloy, Noémie Laverdure, Cécile Picard, Alexandre Belot
Abstract not available
-
Exploring Preconceptions as Barriers to Peritoneal Dialysis Eligibility: A Global Scenario-Based Survey of Kidney Care Physicians Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-02 Nikhil Shah, Paul N. Bennett, Yeoungjee Cho, Saskia Leibowitz, Graham Abra, Talerngsak Kanjanabuch, Jyoti Baharani
Despite growing number of patients requiring kidney replacement therapy peritoneal dialysis (PD) is underutilized globally. A contributory factor may be clinician myths around its use. The aim of this study was to explore perceptions around PD initiation by clinicians according to various physical, social and clinical characteristics of patients. An online global survey (English, Thai) was administered
-
Clinical Relevance of Anti-C3 and Anti-C4 Autoantibodies in Lupus Nephritis Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-02 Vasil Vasilev, Mikel Rezola Artero, Marijana Petkova, Galya Mihaylova, Marie-Agnes Dragon-Durey, Maria Radanova, Lubka T. Roumenina
Complement system overactivation is pivotal in LN pathophysiology. As anti-C3 autoantibodies play a significant role in LN pathophysiology, we explored them as disease activity biomarkers and compared them to the ones against the homologous protein C4. We investigated the presence of anti-C3 and anti-C4 IgG autoantibodies in a LN cohort (n=85 patients) and monitored their changes over time. We correlated
-
Lithium-Associated Kidney Failure: Predictors and Outcomes Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-02 Emily Qian, Kamal Sud, Vincent Lee
Despite the widespread use of lithium for bipolar disorders and depression, little is known regarding the characteristics of patients with lithium-associated kidney failure receiving kidney replacement therapy (KRT). We conducted a retrospective study using the Australian and New Zealand Dialysis and Transplant Registry (ANZDATA) to investigate the predictors and outcomes of patients with lithium-associated
-
Corrigendum to “Changing Phenotypes and Clinical Outcomes Over Time in Microscopic Polyangiitis” [Kidney International Reports Volume 8, Issue 10, October 2023, Pages 2107-2116] Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-02 Martina Uzzo, Umberto Maggiore, Filippo Sala, Francesco Reggiani, Vincenzo L'Imperio, Federica Deliso, Marta Calatroni, Gabriella Moroni, Renato A. Sinico
Abstract not available
-
Pregnancies in Women With Kidney Failure on Home Dialysis in the United States Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-01 Silvi Shah, Eric Weinhandl, Anthony C. Leonard, Brenna Rachwal, Prasoon Verma, Jeffrey Perl, Annette L. Christianson
-
Impact of Age 70 years or Older on Donors for Living-Donor Kidney Transplantation Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-01 Takahisa Hiramitsu, Tomoki Himeno, Yuki Hasegawa, Kenta Futamura, Manabu Okada, Yutaka Matsuoka, Norihiko Goto, Toshihiro Ichimori, Shunji Narumi, Asami Takeda, Takaaki Kobayashi, Kazuharu Uchida, Yoshihiko Watarai
Kidney transplantation (KT) involving elderly living kidney donors (LKDs) is becoming more frequent because of a profound organ shortage. The efficacy of KT involving grafts obtained from LKDs 70 years of age or older has been reported. However, the safety of donor nephrectomy in LKDs 70 years of age or older, including that associated with changes in the estimated glomerular filtration rate (eGFR)
-
What is the Appropriate Dose of Tolvaptan in ADPKD? Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-01 Neera K. Dahl, Vicente E. Torres
Abstract not available
-
Socioeconomic Position and Health Among Children and Adolescents With CKD Across the Life-Course Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-01 Anita van Zwieten, Siah Kim, Amanda Dominello, Chandana Guha, Jonathan C. Craig, Germaine Wong
Children and adolescents in families of lower socioeconomic position (SEP) experience an inequitable burden of reduced access to healthcare and poorer health. For children living with chronic kidney disease (CKD), disadvantaged SEP may exacerbate their considerable disease burden. Across the life-course, CKD may also compromise the SEP of families and young people, leading to accumulating health and
-
Racialized and Immigrant Status and the Pursuit of Living Donor Kidney Transplant - a Canadian Cohort Study Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-01 Eric Lui, Jasleen Gill, Marzan Hamid, Cindy Wen, Navneet Singh, Princess Okoh, Xihui Xu, Priscilla Boakye, Carl E. James, Amy D. Waterman, Beth Edwards, Istvan Mucsi
-
Competing Risks Analysis of Kidney Transplant Waitlist Outcomes: Two Important Statistical Perspectives Kidney Int. Rep. (IF 6.0) Pub Date : 2024-02-01 Jeffrey J. Gaynor, Giselle Guerra, Rodrigo Vianna, Marina M. Tabbara, Enric Lledo Graell, Gaetano Ciancio
Modern competing risks analysis has 2 primary goals in clinical epidemiology: to maximize the clinician’s knowledge of etiologic associations existing between potential predictor variables and various cause-specific outcomes via cause-specific hazard models, and to maximize the clinician’s knowledge of noteworthy differences existing in cause-specific patient risk via cause-specific subdistribution